United States Food and Drug Administration (USFDA) has successfully completed regulatory inspection of Natco Pharma’s Active Pharmaceutical Ingredient (API) facility in Mekaguda Village, Hyderabad.
The inspection was conducted during the period February 12-16, 2018. The regulatory audit resulted in zero observations.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
